Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
40
about 2.2 years
18–40
1 site in VA
What this study is about
Researchers are testing whether artificial pancreas technology can improve blood sugar control, reduce blood glucose variability, and potentially benefit cardiovascular health in people with type 1 diabetes. The trial will evaluate if improvements in blood sugar levels lead to a decrease in inflammation and other markers of heart disease risk.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Sensor augmented pump (SAP) therapy
- 2.Use Tandem t:slim X2 with Control-IQ Technology
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Brachial artery flow-mediated dilation (FMD), Carotid Femoral Pulse Wave Velocity (cfPWV), High-sensitivity C-reactive protein (hs-CRP), Insulin sensitivity, Interleukin-6 (IL-6), Myocardial Perfusion (measured by contrast-enhanced ultrasound [CEU])
Endocrinology